Endo International (ENDP) Launches Ready-to-Use VASOSTRICT

• First and only manufacturer-prepared, FDA approved vasopressin in a premixed ready-to-use (RTU) format
• RTU format does not require diluting, or transferring, which may reduce waste and chance of preparation error that could impact a patient's health
• Two-year shelf life1, with up to 12 months at room temperature2*, may offer enhanced health systems' inventory management

Endo International plc (NASDAQ: ENDP) announced today that its Par Sterile Products business has begun shipping VASOSTRICT®, vasopressin injection, USP, in ready-to-use 100 mL pre-mix bottles. It's the first and only ready-to-use formulation of the drug.

"Our partners in healthcare are working harder than ever; this new ready-to-use bottle allows them to focus more of their time on what matters most—patient care," said Scott Sims, Senior Vice President and General Manager, Sterile Products at Endo. "Our team remains dedicated to meeting the evolving needs of healthcare providers."

Ready-to-use, or RTU, products help streamline operations for hospitals by eliminating the need to prepare or transfer the product before patient administration. This may reduce waste and costs, optimize convenience and workflow, and heighten accuracy and compliance by reducing the chance for preparation error—all of which support quality patient care.

This new VASOSTRICT® formulation has a two-year shelf life1, with up to 12 months at room temperature2*, which may offer enhanced inventory management in addition to the other advantages of an RTU formulation/presentation.

* Store between 2°C and 8°C (36°F and 46°F). Vials may be held up to 12 months upon removal from refrigeration to room temperature storage conditions (20°C to 25°C [68°F to 77°F]).

You May Also Be Interested In

• Fate Therapeutics starts Phase 2 lupus nephritis trial of FT819
• Quantum BioPharma gets FDA nod for Lucid-MS Phase 2 MS trial
• Belite Bio (BLTE) Reiterated at Buy by Benchmark on Tinlarebant NDA Acceptance by FDA